Codagenix Inc.
Live attenuated RSV vaccine (MinL4.0) engineered through synthetic gene deoptimization
- Sector
- Biotech
- Headquarters
- Great Neck, NY
- Latest Form D
- $25M, Feb 2023
- Total capital
- $50.2M
- Federal grants
- $14M
- 18 awards · 2014–2022
- Rank in peer group#175 of 514
- Private capital raised
- $25M
- 1 Form D · last Feb 2023
- 44 months since last filing
- Federal contracts
- $11.2M
- 4 awards · Defense, Health and Human S
- Rank in Biotech#58 of 4373
- Granted patents
- 6
- 34 pending · first 2020
- Rank in peer group#58 of 514
Capital timeline
Latest events
- Federal contractHealth and Human S · Conduct A Phase 2B Efficacy Study As Prescribed In AOI15 With Coviliv A Proprietary Live Attenuated Virus COVID-19 Vaccine.$10M
- Private capital raisedForm D · SEC · 1st filing$25M
- Federal grantHealth and Human S · Phase II · A rationally-designed, live-attenuated RSV vaccine for the elderly$809K
- Federal grantHealth and Human S · Phase II · A rationally-designed, live-attenuated RSV vaccine for the elderly$665K
- Federal grantHealth and Human S · Phase II · Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine$999K
- Federal grantHealth and Human S · Phase II · Rapid generation and testing of live-attenuated vaccines against SARS-CoV-2$1.7M
- Federal grantHealth and Human S · Phase II · A rationally-designed, live-attenuated RSV vaccine for the elderly$727K
Show 15 earlier federal awards
- Federal grantHealth and Human S · Phase II · A rationally-designed, live-attenuated RSV vaccine for the elderly$3.9M
- Federal contractDefense · Army 17.1 SBIR Phase II Medical R&d Contract For Proposal #A2-7469, Titled "development Of A Flexible, Live Tetravalent Dengue Vaccine" ERMS18263006$948K
- Federal grantDefense · Phase II · Development of a Flexible, Live Tetravalent Dengue Vaccine$948K
- Federal grantHealth and Human S · Phase II · Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine$745K
- Federal contractDefense · Igf::ot::igf Army SBIR Ph I Proposal A171-067-0379 Development Of A Balanced And Efficacious Live-attenuated Tetravalent Dengue Vaccine ERMS17152008$149K
- Federal grantAgriculture · Commercialization Of A Synthetic, Tri-valent Live-attenuated Swine-influenza Vaccine$593K
- Federal grantHealth and Human S · Phase II · Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine$755K
- Federal contractDefense · Igf::ot::igf Research Scientist Mfr Dengue Vaccine.$64K
- Federal grantAgriculture · Commercialization Of A Synthetic, Live-attenuated Fmdv Vaccine$598K
- Federal grantAgriculture · Commercialization Of A Synthetic, Live-attenuated Fmdv Vaccine$598K
- Federal grantAgriculture · Rational Design Of A Broadly Protective Live Attenuated Influenza A Vaccine For Use In Swine$100K
- Federal grantAgriculture · Commercialization Of A Synthetic, Live-attenuated Fmdv Vaccine$100K
- Federal grantHealth and Human S · Phase I · Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology$296K
- Federal grantHealth and Human S · Phase I · Ultra-low dose Influenza vaccines$200K
- Federal grantHealth and Human S · Phase I · Balancing Immunogenicity of a Tetravalent Live Attenuated Dengue Vaccine$223K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Federal first
99months
from Codagenix Inc.’s first federal award to its first private round.
- First federal award · Dec 2014
- Health and Human S · $223K
- First Form D · Feb 2023
- $25M · 1st Form D
- Awards before first raise
- 20 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#175 · top 34%
- Granted patents#58 · top 11%
- Linked publications#68 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Steffen Robert MuellerResearcherDirectorLinked by $11.7M in grants as PI
- Charlie Robert PettyDirectorNamed in SEC Form D filings
- Glenn Robert RockmanDirectorNamed in SEC Form D filings
- Jill Robert HoweDirectorNamed in SEC Form D filings
- John Robert ColemanExecutive Officer, DirectorNamed in SEC Form D filings
- Lori Robert Rudolph-OwenDirectorNamed in SEC Form D filings
Show all 9 people
- Paul Robert GrintDirectorNamed in SEC Form D filings
- Steven Robert WinickDirectorNamed in SEC Form D filings
- Tyler Robert CookExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingDeoptimized Influenza Viruses And Methods Of Treating CancerUSPTOApplication 18856367
- PendingFreeze-dried Viral Combination Vaccine Compositions And Process For Preparation ThereofUSPTOApplication 18690297
- PendingParenterally Administrable Influenza Vaccine And Uses ThereofUSPTOApplication 18714291
Show all 40 patent records
- Deoptimized Influenza Viruses And Methods Of Treating CancerOct 23, 2025 · Application 18856367Pending
- Freeze-dried Viral Combination Vaccine Compositions And Process For Preparation ThereofFeb 20, 2025 · Application 18690297Pending
- Parenterally Administrable Influenza Vaccine And Uses ThereofJan 23, 2025 · Application 18714291Pending
- Recombinant Virus With Codon-pair Deoptimized Region And Uses Thereof For The Treatment Of CancerDec 31, 2024 · US 12,178,869Granted
- Vaccine Candidates For Human Respiratory Syncytial Virus (rsv) Having Attenuated PhenotypesDec 19, 2024 · Application 18758660Pending
- Attenuated FlavivirusesDec 17, 2024 · US 12,168,049Granted
- Deoptimized Yellow Fever Virus And Methods And Uses ThereofSep 5, 2024 · Application 18572482Pending
- Vaccine Candidates For Human Respiratory Syncytial Virus (rsv) Having Attenuated PhenotypesAug 6, 2024 · US 12,054,519Granted
- Method Of Eliciting An Immune Response Against Respiratory Syncytial VirusMay 23, 2024 · Application 18283130Pending
- Method Of Producing Modified Virus Genomes And Producing Modified VirusesOct 26, 2023 · Application 18010740Pending
- Live Attenuated Strains Of Foot And Mouth Disease Modified By Deoptimization And Uses ThereofOct 24, 2023 · US 11,793,870Granted
- Attenuated Dengue VirusesNov 3, 2022 · Application 17621125Pending
- Attenuated Yellow Fever Virus And Uses Thereof For The Treatment Of CancerAug 4, 2022 · Application 17610026Pending
- Vaccine Candidates For Human Respiratory Syncytial Virus (rsv) Having Attenuated PhenotypesJul 19, 2022 · US 11,390,651Granted
- Vaccine Candidates For Human Respiratory Syncytial Virus (rsv) Having Attenuated PhenotypesOct 20, 2020 · US 10,808,012Granted
- Method Of Eliciting An Immune Response Against Respiratory Syncytial VirusApplication PCTUS2022024068Pending
- Parenternally Administrable Influenza Vaccine And Uses ThereofApplication 63285398Pending
- DEOPTIMIZED SARS-CoV-2 VARIANTS AND METHODS AND USES THEREOFApplication 63219263Pending
- Deoptimized Yellow Fever Virus And Method And Uses ThereofApplication 63219256Pending
- Method Of Producing Modified Virus Genomes And Producing Modified VirusesApplication PCTUS2021040716Pending
- Live Attenuated Strains Of Foot And Mouth Disease Modified By Deoptimization And Uses ThereofApplication PCTUS2021034282Pending
- Parenterally Administrable Influenza Vaccine And Uses ThereofApplication PCTUS2022080808Pending
- Method Of Eliciting An Immune Response Against Respiratory Syncytial VirusApplication 63172540Pending
- DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOFApplication 63079337Pending
- DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOFApplication 63079853Pending
- Deoptimized Influenza Viruses And Methods Of Treating CancerApplication 63429652Pending
- Method Of Producing Modified Virus Genomes And Producing Modified VirusesApplication 63048947Pending
- DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOFApplication 63048942Pending
- Attenuated Dengue VirusesApplication PCTUS2020039166Pending
- Deoptimized Influenza Viruses And Methods Of Treating CancerApplication PCTUS2023065949Pending
- Live Attenuated Strains Of Foot And Mouth Disease Modified By Deoptimization And Uses ThereofApplication 63030431Pending
- Attenuated Yellow Fever Virus And Uses Thereof For The Treatment Of CancerApplication PCTUS2020032901Pending
- Codon Deoptimized And Codon Pair Deoptimized Wuhan Coronavirus And Uses ThereofApplication 62966750Pending
- Attenuated Dengue VirusesApplication 62866477Pending
- Attenuated Yellow Fever Virus And Uses Thereof For The Treatment Of CancerApplication 62848443Pending
- Attenuated FlavivirusesApplication PCTUS2018067114Pending
- Recombinant Virus With Codon-pair Deoptimized Region And Uses Thereof For The Treatment Of CancerApplication PCTUS2018067174Pending
- Recombinant Virus With Codon-pair Deoptimized Region And Uses Thereof For The Treatment Of CancerApplication 62677132Pending
- Attenuated FlavivirusesApplication 62640355Pending
- Recombinant Virus With Codon-pair Deoptimized Region And Uses Thereof For Oncolytic PurposesApplication 62640362Pending
Recent research by its founders
- Short‐stature maize systems reduce carbon intensity of grain production by an average of 13% compared to commercially relevant tall comparators20253 cites
- Biofuels Induced Land Use Change Emissions: The Role of Implemented Land Use Emission Factors20249 cites
- Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters20245 cites
Related companies, and why
- ZATA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12.6M in contracts
- INOVIO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12M in contracts
- Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts
- Ceramedix Holding, LLCSimilar federal contract value in Biotech · $10.2M in contracts
- SACHI BIOWORKS, INC.Similar federal contract value in Biotech · $9.8M in contracts
- INNOVATION PATHWAYS, LLCSimilar federal contract value in Biotech · $9.2M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .